DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?
| Status: | Archived |
|---|---|
| Conditions: | Insomnia Sleep Studies, Pulmonary |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2009 |
| End Date: | March 2011 |
Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea? DREAM-A Pilot Study
This study is being conducted to find out if the use of inhaled corticosteroids has an
affect on upper airway collapsibility and sleep apnea risk. An inhaled corticosteroid is a
common asthma controller medication like Flovent. Sleep apnea is w hen someone stops
breathing for a short period of time during sleep. For some reason, people with asthma have
more sleep apnea and upper airway collapsibility (weakness) than the general population.
There are many possible reasons for this and one might be related to the use of inhaled
corticosteroids.
The overall hypothesis of this study is to determine whether inhaled fluticasone propionate
(FP) increases UAW collapsibility and to assess tongue (genioglossus muscle) dysfunction as
a potential underlying mechanism.
To address this hypothesis, we specifically aim is to determine the effects of 16 weeks of
treatment with inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 880
mcg twice daily, on:
Specific Aim 1: UAW collapsibility, as measured by Pcrit during NREM sleep; Specific Aim 2:
Severity of obstructive SDB and sleep quality, and quality of life related to sleep apnea
assessed on validated questionnaires (Sleep Apnea scale of the Sleep Disorders Questionnaire
[SA-SDQ], Epworth Sleepiness Scale [ESS]) and Pittsburgh Sleep Quality Index [PSQI], and
Sleep Apnea Quality of Life Index [SAQLI]); Specific Aim 3: Tongue strength and fatigability
(assessed using the Iowa Oral Performance Instrument)
We found this trial at
1
site
Click here to add this to my saved trials
